{"gene":"MAP2K2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2004,"finding":"Crystal structures of human MEK1 and MEK2 each determined as ternary complexes with MgATP and an inhibitor reveal a unique allosteric inhibitor-binding pocket adjacent to the ATP-binding site. The inhibitor induces conformational changes that lock unphosphorylated MEK1 and MEK2 into a closed but catalytically inactive species, establishing a noncompetitive mechanism for kinase inhibition.","method":"X-ray crystallography (2.4 Å for MEK1, 3.2 Å for MEK2)","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with functional validation, two isoforms solved, established novel mechanism","pmids":["15543157"],"is_preprint":false},{"year":1993,"finding":"Human MEK2 was cloned and shown to be a dual-specificity kinase that phosphorylates ERK1 on both threonine and tyrosine residues, activating ERK1 kinase activity more than 100-fold in vitro. Recombinant MEK2 can be activated by serum-stimulated cell extract in vitro.","method":"In vitro kinase assay with recombinant proteins expressed in E. coli","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution of enzymatic activity, replicated by multiple independent cloning papers in same year","pmids":["8388392","8393135","8297798"],"is_preprint":false},{"year":1993,"finding":"MEK2 (MKK2) can be phosphorylated and activated by v-Raf in vitro, and both MEK1 and MEK2 are activated in vivo in response to serum, establishing Raf as an upstream activator of MEK2.","method":"In vitro kinase assay; in vivo activation assay in COS cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro phosphorylation assay plus in vivo confirmation, replicated across multiple early studies","pmids":["8393135","8388392"],"is_preprint":false},{"year":1995,"finding":"MEKK1 catalytic domain phosphorylates MEK1 and MEK2 activation-loop serines (S218/S222 equivalents) in vitro and interacts with MEK1 in the two-hybrid system. Expression of MEKK1 in mammalian cells causes constitutive activation of both MEK1 and MEK2, although downstream ERK2 activation is modest compared to EGF stimulation.","method":"In vitro kinase assay, yeast two-hybrid, transfection in mammalian cells with Western blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (in vitro assay, two-hybrid, cell-based activation), identified phosphorylation sites","pmids":["7624324"],"is_preprint":false},{"year":1995,"finding":"A proline-rich (PR) sequence unique to MEK1 and MEK2 is required for Raf family binding and MEK activation. Deletion of the PR sequence from MEK1 blocked association with Raf and markedly attenuated growth factor-induced activation. A phosphorylation site within the PR sequence of MEK1 sustains activity, whereas MEK2 lacks this site and shows only transient activation after serum stimulation.","method":"Deletion mutagenesis, co-immunoprecipitation, in vivo kinase assays in fibroblasts","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple mutants tested, reciprocal interaction experiments, functional readout of transformation","pmids":["7565670"],"is_preprint":false},{"year":1994,"finding":"RAS and RAF-1 form a signaling complex with MEK1 but not MEK2. MEK-2 was not detected in the RAS:RAF-1:MEK-1 complex, and consistent with this, basal MEK2 activity in v-ras-transformed cells was elevated only twofold vs. sixfold for MEK1, indicating differential coupling of MEK1 and MEK2 to the RAS signaling complex.","method":"Immobilized RAS pulldown, co-immunoprecipitation from cell lysates, kinase activity assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal pulldown and activity measurements, finding replicated in selectivity literature","pmids":["7969158"],"is_preprint":false},{"year":1996,"finding":"A-Raf selectively phosphorylates and activates MEK1 but not MEK2 upon EGF stimulation of HeLa cells, whereas c-Raf activates both MEK1 and MEK2. Using MEK1-S218/222A as bait in yeast two-hybrid screens, all three Raf isoforms were identified as MEK1 interactors.","method":"Yeast two-hybrid screening, in vitro kinase assay, EGF stimulation of HeLa cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — yeast two-hybrid plus in vitro kinase assay, isoform-selective result","pmids":["8621729"],"is_preprint":false},{"year":2006,"finding":"The Yersinia effector YopJ acetylates two serine residues in the activation loop of MEK2, preventing their phosphorylation required for MEK2 activation. This covalent acetylation is the mechanism by which YopJ blocks MAPK signaling.","method":"Mass spectrometry-based identification of acetylation sites, biochemical inhibition assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — novel covalent modification characterized by MS with functional consequence, single lab but clear mechanistic readout","pmids":["17116858"],"is_preprint":false},{"year":2009,"finding":"MEK1 and MEK2 form a heterodimer in which MEK1 downregulates MEK2-dependent ERK signaling. ERK phosphorylates MEK1 at Thr292 (a residue absent in MEK2), creating a negative feedback that also reduces MEK2 phosphorylation within the heterodimer. Loss of MEK1 stabilizes MEK2 phosphorylation and sustains ERK activation in cultured cells and in vivo.","method":"Co-immunoprecipitation, phospho-specific Western blot, MEK1 knockout mouse embryos, site-directed mutagenesis of Thr292","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP establishing heterodimer, mutagenesis of feedback site, in vivo confirmation in KO mice, multiple orthogonal methods","pmids":["19219045"],"is_preprint":false},{"year":2007,"finding":"MEK1-activated ERK2 accumulates in the nucleus and promotes proliferation, whereas MEK2-activated ERK2 is retained in the cytoplasm and supports cell survival. MEK1-mediated nuclear translocation of ERK2 depends on phosphorylation of MEK1 residues S298 (by PAK) and T292 (by ERK2 feedback), sites present in MEK1 but not MEK2.","method":"siRNA knockdown, nuclear export sequence constructs, immunofluorescence/subcellular fractionation, phospho-site mutagenesis","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (siRNA, localization, mutagenesis), isoform-specific localization with functional consequence","pmids":["17928366"],"is_preprint":false},{"year":2008,"finding":"Upon EGF receptor activation, a pool of MEK2 is recruited to the plasma membrane and then to early and late endosomes via clathrin-dependent endocytosis. RAF kinase activity and MEK catalytic activity are required for endosomal targeting of MEK2. Clathrin knockdown abolishes MEK2 endosomal recruitment and increases ERK activation, suggesting endosomal MEK2 participates in negative feedback regulation.","method":"GFP-tagged MEK2 live imaging, siRNA knockdown of clathrin and RAF, fluorescence microscopy in HeLa cells","journal":"Traffic","confidence":"High","confidence_rationale":"Tier 2 / Strong — live-cell imaging with GFP-MEK2, siRNA knockdowns, functional ERK readout, multiple perturbations","pmids":["18657070"],"is_preprint":false},{"year":2018,"finding":"The deubiquitinase USP21 stabilizes MEK2 by removing Lys48-linked polyubiquitin chains from MEK2, preventing its proteasomal degradation and thereby sustaining ERK signaling.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, ectopic expression in cell lines","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and ubiquitination assay in single lab, mechanistic site (K48 linkage) identified but mutagenesis of specific ubiquitin sites not described in abstract","pmids":["29706623"],"is_preprint":false},{"year":2014,"finding":"The small GTPase RBJ interacts with MEK1/MEK2 in the nucleus, prolongs MEK/ERK activation by nuclear entrapment, and promotes carcinogenesis. RBJ deficiency abrogates nuclear accumulation of MEK1/MEK2 and attenuates ERK1/ERK2 activation.","method":"Co-immunoprecipitation, subcellular fractionation, RBJ knockout mouse model, tumor model","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, fractionation, in vivo KO model, single lab","pmids":["24746703"],"is_preprint":false},{"year":2010,"finding":"Active MEK2 (but not kinase-dead MEK2) serves as a scaffold that bridges Pin1 and BPGAP1, promoting Pin1 binding to BPGAP1 to suppress acute ERK activation and cell migration. Only catalytically active MEK2 can bind Pin1, and this interaction requires release of an autoinhibited proline-rich motif in BPGAP1.","method":"Co-immunoprecipitation, kinase-dead and constitutively active MEK2 mutants, siRNA knockdown, cell migration assay","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with active vs kinase-dead mutants, functional readout, single lab","pmids":["20179103"],"is_preprint":false},{"year":2011,"finding":"The human Discs-large tumor suppressor hDlg interacts with the phosphorylated (active) form of MEK2 at the midbody ring during cytokinesis. The interaction depends on MEK2 phosphorylation and is mediated by the PDZ domains of hDlg binding the C-terminal portion of MEK2. E-cadherin expression is required for isoform-specific recruitment of hDlg (but not active MEK2) to the midbody.","method":"Co-immunoprecipitation, immunofluorescence, cell cycle synchronization, E-cadherin knockdown","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, localization, E-cadherin dependency test; single lab","pmids":["22185284"],"is_preprint":false},{"year":2021,"finding":"MEK2 directly interacts with and phosphorylates the tumor suppressor GCIP at Ser313 and Ser356, promoting ubiquitin-mediated proteasomal degradation of GCIP and enhancing cancer cell proliferation and migration.","method":"Co-immunoprecipitation, in vitro kinase assay, phospho-site mutagenesis, ubiquitination assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation with site mutagenesis plus ubiquitination/degradation readout, multiple orthogonal methods in single lab","pmids":["31907980"],"is_preprint":false},{"year":2012,"finding":"MEK2 physically interacts with ribonucleotide reductase small subunit p53R2 and upregulates RNR enzymatic activity. The MEK2 segment comprising amino acids 65–171 is critical for p53R2-MEK2 interaction. Ionizing radiation augments MEK2 phosphorylation and concurrently increases RNR activity in a MEK2-dependent manner.","method":"Co-immunoprecipitation, deletion mapping, MEK inhibitor treatment, siRNA knockdown, RNR activity assay","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, activity assay, siRNA confirmation; single lab","pmids":["22895183"],"is_preprint":false},{"year":2021,"finding":"MEK2 is O-GlcNAcylated at Thr13 by OGT. O-GlcNAcylation at Thr13 (located in the docking domain) enhances MEK2 Thr394 phosphorylation and downstream ERK1/2 activation. Ablation of Thr13 O-GlcNAcylation abolishes MEK2-driven proliferation and migration of breast cancer cells.","method":"Mass spectrometry identification of O-GlcNAc site, site-directed mutagenesis, Western blot, cell proliferation/migration assay","journal":"Glycobiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — MS identification of modification site, mutagenesis, functional readout; single lab but multiple orthogonal methods","pmids":["33226073"],"is_preprint":false},{"year":2002,"finding":"A-Raf interacts with MEK2 through its kinase domain (residues 255–606), as identified by yeast two-hybrid screening and confirmed by in vitro binding assay.","method":"Yeast two-hybrid, in vitro binding assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2–3 / Weak — yeast two-hybrid plus in vitro pulldown, but single lab and no functional phosphorylation readout for MEK2","pmids":["11909642"],"is_preprint":false},{"year":1996,"finding":"MEK2 is the predominant MEK isoform activated in human neutrophils by chemotactic peptides, with activity at least 3-fold greater than MEK1. MEK2 activation is more sensitive to the PI3-kinase inhibitor wortmannin than MEK1, indicating differential upstream regulation, and both isoforms are activated by PKC agonists.","method":"Immunoprecipitation kinase assay, pharmacological inhibition, fMLP stimulation of primary neutrophils","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — isoform-specific immunoprecipitation kinase assays, multiple inhibitors tested; single study","pmids":["8702863"],"is_preprint":false},{"year":2010,"finding":"MEK2, but not MEK1, controls MKK3/MKK6-p38 MAPK axis phosphorylation in MDA-MB-231 breast cancer cells independent of ERK1/2 activation. MEK2 silencing decreases cyclin D1 expression and increases apoptosis, while MEK1 silencing has the opposite effect.","method":"siRNA knockdown of MEK1 and MEK2 individually, Western blot for p38, MKK3/6 phosphorylation, cell viability assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — isoform-specific siRNA with phosphoprotein readout, unexpected non-ERK pathway identified; single lab","pmids":["27181679"],"is_preprint":false},{"year":2010,"finding":"MEK2 acts upstream of PI3Kδ in IFN-β-stimulated human monocytes to regulate IL-1Ra production. Blockade of MEK2 (but not MEK1) prevented PI3Kδ membrane recruitment, Akt phosphorylation, and IL-1Ra production. ERK1/2 are dispensable for this pathway, suggesting a non-canonical MEK2 signaling function.","method":"MEK isoform-selective inhibitors, siRNA knockdown, subcellular fractionation, immunoprecipitation in primary human monocytes","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA plus pharmacological inhibition with membrane fractionation; novel pathway but single lab","pmids":["20837746"],"is_preprint":false},{"year":2019,"finding":"MEK2 inversely and independently regulates HIF-1α expression and IL-1β production in LPS-stimulated macrophages. MEK2-deficient bone marrow-derived macrophages show preserved ERK1/2 phosphorylation but higher HIF-1α, Glut1, and IL-1β levels. Overexpression of MEK2 in RAW264.7 cells decreases IL-1β production after LPS stimulation, establishing MEK2 as a negative regulator of HIF-1α/IL-1β independent of ERK.","method":"MEK2 knockout macrophages, siRNA knockdown of HIF-1α, MEK2 overexpression, Western blot, cytokine ELISA","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse-derived macrophages plus gain-of-function, siRNA epistasis; single lab with multiple approaches","pmids":["30710049"],"is_preprint":false},{"year":2016,"finding":"TRNA interacts with MEK2 in pancreatic cancer cells, and the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction. tRNA modulates MEK2 catalytic activity differently for wild-type and cancer-associated mutant forms (Q60P, P128Q, S154F, E207K).","method":"Co-immunoprecipitation, in vitro kinase activity assay, MEK2 mutant constructs","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and activity assay, unusual finding not replicated, single lab","pmids":["27301426"],"is_preprint":false},{"year":2003,"finding":"Mek2-null mice are viable and fertile with no overt morphological defects, demonstrating that MEK2 is dispensable for normal mouse development and that its loss is compensated by MEK1.","method":"Gene targeting (knockout mouse), phenotypic analysis including thymocyte development and T-cell proliferation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean germline knockout with comprehensive phenotypic analysis","pmids":["12832465"],"is_preprint":false},{"year":2009,"finding":"Map2k2 haploinsufficiency in combination with one null Map2k1 allele causes placental defects restricted to extra-embryonic tissues and embryonic lethality. The severity correlates with total MEK protein levels regardless of isoform identity, indicating a dosage threshold effect for placental development.","method":"Compound mutant mouse genetics (allelic series), conditional Map2k1 deletion, histological analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic allelic series in vivo, tissue-specific rescue experiments","pmids":["19304888"],"is_preprint":false},{"year":2016,"finding":"MEK1 and MEK2 are functionally redundant at the protein level: knock-in of Mek2 coding sequences under Mek1 regulatory control rescues Mek1-null lethality, establishing that the embryonic phenotype reflects protein quantity rather than isoform-specific biochemistry.","method":"Knock-in mouse genetics, allelic series analysis, embryo viability assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous knock-in rescue experiment in vivo demonstrating functional redundancy","pmids":["26814233"],"is_preprint":false},{"year":2022,"finding":"MAP2K2 (MEK2) in myeloid/leukocyte cells delays resolution of acute lung injury. Mek2-/- mice show faster resolution of alveolar neutrophilia and vascular leak following Pseudomonas aeruginosa injury. Bone marrow chimera studies confirm leukocyte MAP2K2 as the key regulator of ALI duration.","method":"Mek2-null mouse model, bone marrow chimera, acute lung injury models, gene expression analysis","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with bone marrow chimera to define cell compartment, single lab","pmids":["35157553"],"is_preprint":false},{"year":1996,"finding":"ERK1 residues flanking its regulatory phosphorylation sites determine specificity of recognition and phosphorylation by MEK1 and MEK2. Mutation of Arg-208 dramatically increases tyrosine phosphorylation while eliminating threonine phosphorylation; mutation of Gly-199 increases threonine vs. tyrosine phosphorylation, demonstrating that the phosphorylation lip of ERK is a determinant of MEK substrate recognition.","method":"Site-directed mutagenesis of ERK1, in vitro phosphorylation assay with MEK1 and MEK2","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with in vitro phosphorylation assay, multiple mutants tested, single lab","pmids":["8626767"],"is_preprint":false},{"year":2011,"finding":"MEK2 is sufficient to sustain ERK activation, proliferation, and anchorage-independent growth of SK-MEL-28 melanoma cells when other MKKs are cleaved by anthrax lethal toxin. MEK1 and MEK2 drive non-overlapping downstream transcriptional programs in these cells.","method":"Anthrax lethal toxin MEK cleavage, protease-resistant MEK mutants (MEK1cr, MEK2cr), microarray transcriptomics, proliferation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — elegant gain-of-function experimental design with protease-resistant mutants, microarray readout; single lab","pmids":["21365009"],"is_preprint":false},{"year":2020,"finding":"In Pelizaeus-Merzbacher disease model mice, oligodendrocyte-specific expression of a kinase-deficient dominant-inhibitory MEK2 mutant (MEK2K101A) promotes CNS myelination and improves motor coordination, establishing that MEK2 signaling suppresses oligodendrocyte differentiation and myelination.","method":"Transgenic mouse expressing kinase-dead MEK2K101A in oligodendrocytes, histological myelination analysis, Rotarod behavioral testing","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo transgenic approach with functional behavioral readout, but single lab and single method","pmids":["32800341"],"is_preprint":false},{"year":2024,"finding":"MEK2, but not MEK1, mediates uptake of breast cancer cell-derived extracellular vesicles by lung fibroblasts through a macropinocytosis mechanism. Gene knockdown and overexpression studies established MEK2 as required for this process.","method":"siRNA knockdown, MEK2 overexpression, high-content microscopy, macropinocytosis assay","journal":"Cancer research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — loss-of-function and gain-of-function with defined cellular readout; single lab","pmids":["38259097"],"is_preprint":false}],"current_model":"MAP2K2 (MEK2) is a dual-specificity kinase that phosphorylates ERK1/2 on both threonine and tyrosine residues to activate them; it is structurally characterized by a unique allosteric inhibitor pocket that locks the enzyme in a catalytically inactive conformation, is activated by Raf-family kinases (c-Raf, B-Raf) and MEKK1 via activation-loop serine phosphorylation, forms a heterodimer with MEK1 through which ERK-mediated feedback phosphorylation of MEK1-Thr292 indirectly dampens MEK2 activity, and undergoes additional post-translational regulation including activation-loop acetylation by bacterial YopJ, O-GlcNAcylation at Thr13 that enhances activity, and Lys48-linked polyubiquitination reversed by USP21; subcellularly, MEK2 is recruited to endosomes in a RAF- and clathrin-dependent manner as part of negative feedback, is retained in the nucleus by the small GTPase RBJ to prolong ERK signaling, and directs ERK2 to the cytoplasm for survival rather than the nucleus for proliferation; beyond ERK, MEK2 engages non-canonical substrates including p53R2/RNR, GCIP, and the PI3Kδ pathway, and plays essential roles in placental development and erythropoiesis in a dosage-dependent manner with MEK1."},"narrative":{"mechanistic_narrative":"MAP2K2 (MEK2) is a dual-specificity protein kinase that phosphorylates ERK1/2 on both threonine and tyrosine within their activation lip, switching them on more than 100-fold and thereby relaying RAS-RAF signaling to the ERK MAP kinase cascade [PMID:8388392, PMID:8393135, PMID:8297798, PMID:8626767]. It is activated through phosphorylation of two activation-loop serines by Raf-family kinases (c-Raf, v-Raf) and by MEKK1, with c-Raf engaging MEK2 while A-Raf selectively favors MEK1 [PMID:8393135, PMID:8388392, PMID:7624324, PMID:8621729]. Crystal structures of MEK2 reveal a unique allosteric pocket adjacent to the ATP site where inhibitors lock the unphosphorylated enzyme in a closed, catalytically inactive conformation, defining a noncompetitive inhibition mechanism [PMID:15543157]. MEK2 activity is further tuned by post-translational modifications: O-GlcNAcylation at Thr13 by OGT enhances activation-loop phosphorylation and downstream ERK signaling [PMID:33226073], USP21 removes Lys48-linked polyubiquitin to stabilize MEK2 and sustain ERK output [PMID:29706623], and the bacterial effector YopJ acetylates the activation-loop serines to block phosphorylation and shut down signaling [PMID:17116858]. MEK2 functions in dynamic balance with MEK1: the two form a heterodimer in which ERK feedback phosphorylation of the MEK1-specific Thr292 dampens MEK2 phosphorylation, and MEK2-activated ERK2 is biased toward cytoplasmic retention and survival rather than the nuclear, proliferative output driven by MEK1 [PMID:19219045, PMID:17928366]. Beyond canonical ERK activation, MEK2 phosphorylates the tumor suppressor GCIP to drive its degradation [PMID:31907980], scaffolds Pin1–BPGAP1 complexes to restrain ERK activation and migration [PMID:20179103], regulates ribonucleotide reductase via p53R2 binding [PMID:22895183], and acts through ERK-independent routes on the MKK3/6–p38 axis and the PI3Kδ–IL-1Ra pathway [PMID:27181679, PMID:20837746]. Genetically, MEK2 is dispensable for normal mouse development because MEK1 compensates, yet combined MEK dosage below a threshold causes placental defects and embryonic lethality, and isoform swapping shows MEK1 and MEK2 are functionally redundant at the protein level [PMID:12832465, PMID:19304888, PMID:26814233].","teleology":[{"year":1993,"claim":"Established the core enzymatic identity of MEK2 as a dual-specificity kinase that activates ERK, answering what biochemical step MEK2 performs in the cascade.","evidence":"in vitro kinase assays with recombinant MEK2 phosphorylating ERK1 on Thr and Tyr","pmids":["8388392","8393135","8297798"],"confidence":"High","gaps":["Did not define upstream activators in cells","Did not address MEK1 vs MEK2 functional divergence"]},{"year":1993,"claim":"Placed MEK2 downstream of Raf, defining the canonical RAS-RAF-MEK-ERK linkage for this isoform.","evidence":"in vitro phosphorylation by v-Raf and serum-induced in vivo activation in COS cells","pmids":["8393135","8388392"],"confidence":"High","gaps":["Raf isoform selectivity not resolved","Activation-loop phosphosites not yet mapped"]},{"year":1995,"claim":"Identified MEKK1 as an additional activator and mapped activation-loop serines as the activating sites, clarifying how MEK2 is switched on.","evidence":"in vitro kinase assay, yeast two-hybrid, and mammalian cell activation","pmids":["7624324"],"confidence":"High","gaps":["Physiological versus overexpression contribution of MEKK1 unclear","ERK activation by MEKK1 was modest"]},{"year":1996,"claim":"Revealed isoform-selective upstream coupling — c-Raf activates both MEK1/MEK2 while A-Raf and the RAS:RAF complex favor MEK1 — beginning the distinction between the two MEKs.","evidence":"yeast two-hybrid, in vitro kinase assays, RAS pulldowns, EGF-stimulated HeLa cells","pmids":["8621729","7969158","7565670"],"confidence":"High","gaps":["Functional consequence of differential coupling in vivo not established","Mechanistic basis of selectivity incomplete"]},{"year":1996,"claim":"Defined the substrate-recognition determinants by showing the ERK phosphorylation lip dictates MEK1/MEK2 specificity, explaining the dual-specificity reaction at residue level.","evidence":"site-directed mutagenesis of ERK1 with in vitro phosphorylation","pmids":["8626767"],"confidence":"High","gaps":["MEK2-side recognition residues not mapped","Did not address non-ERK substrates"]},{"year":2003,"claim":"Demonstrated MEK2 is dispensable for development due to MEK1 compensation, framing the redundancy question central to MEK biology.","evidence":"germline Mek2-null mouse with phenotypic analysis","pmids":["12832465"],"confidence":"High","gaps":["Did not test combined MEK dosage","Non-redundant cell-type-specific roles not excluded"]},{"year":2004,"claim":"Provided the structural basis for noncompetitive allosteric inhibition by capturing MEK2 locked in an inactive conformation, defining a druggable pocket.","evidence":"X-ray crystallography of MEK2 ternary complex with MgATP and inhibitor","pmids":["15543157"],"confidence":"High","gaps":["Active phosphorylated-state structure not determined","Conformational dynamics of activation not captured"]},{"year":2006,"claim":"Uncovered covalent regulation of MEK2 by pathogen-driven acetylation of activation-loop serines, revealing a competitive PTM that blocks activating phosphorylation.","evidence":"mass spectrometry mapping of YopJ acetylation sites and biochemical inhibition","pmids":["17116858"],"confidence":"High","gaps":["Endogenous (non-pathogen) acetylation not addressed","Reversibility by host deacetylases unknown"]},{"year":2009,"claim":"Established the MEK1-MEK2 heterodimer and ERK feedback through MEK1-Thr292 as the mechanism by which MEK2 activity is negatively regulated.","evidence":"reciprocal Co-IP, phospho-specific blots, Thr292 mutagenesis, MEK1 knockout embryos","pmids":["19219045"],"confidence":"High","gaps":["Stoichiometry and dynamics of heterodimer in vivo unclear","Whether all MEK2 signaling passes through heterodimer unknown"]},{"year":2007,"claim":"Showed MEK2-activated ERK2 is biased to cytoplasmic, pro-survival output versus MEK1-driven nuclear proliferative output, assigning functional divergence to subcellular ERK fate.","evidence":"siRNA, NES constructs, fractionation/immunofluorescence, phosphosite mutagenesis","pmids":["17928366"],"confidence":"High","gaps":["Molecular basis for cytoplasmic retention by MEK2 incomplete","Generality across cell types not established"]},{"year":2008,"claim":"Localized a MEK2 pool to endosomes via clathrin-dependent endocytosis acting in negative feedback, linking MEK2 trafficking to signal attenuation.","evidence":"GFP-MEK2 live imaging, clathrin/RAF siRNA, ERK readout in HeLa","pmids":["18657070"],"confidence":"High","gaps":["Endosomal substrates of MEK2 not identified","Signal contribution of endosomal pool not quantified"]},{"year":2009,"claim":"Defined a MEK dosage threshold for placental development and embryonic viability, showing combined MEK quantity rather than isoform identity is limiting.","evidence":"compound mutant allelic series with conditional Map2k1 deletion and histology","pmids":["19304888"],"confidence":"High","gaps":["Molecular target requiring high MEK dose in placenta unknown","Tissue-specific thresholds not fully mapped"]},{"year":2016,"claim":"Proved MEK1 and MEK2 are biochemically interchangeable by rescuing Mek1-null lethality with Mek2 coding sequence, settling that phenotypes reflect protein quantity not isoform-specific chemistry.","evidence":"knock-in rescue mouse genetics with embryo viability assays","pmids":["26814233"],"confidence":"High","gaps":["Cannot explain isoform-specific findings in cultured cells","Regulatory (non-coding) differences not addressed"]},{"year":null,"claim":"Multiple ERK-independent and non-canonical MEK2 functions are reported but their integration with the canonical cascade and physiological weight remain unresolved.","evidence":"scattered single-lab studies on GCIP, p53R2/RNR, Pin1-BPGAP1, p38, PI3Kδ, EV uptake, and myelination","pmids":[],"confidence":"Medium","gaps":["Most non-canonical substrates rest on single Co-IP/activity studies without reciprocal validation","Whether kinase activity versus scaffolding drives each function is inconsistent","Reconciliation with strict MEK1/MEK2 redundancy in vivo is unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,3,15,28]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,15]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,8]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9,12]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[10]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,21]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,8]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[10,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[25,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[21,22,27]}],"complexes":["MEK1-MEK2 heterodimer","RAS:RAF-1:MEK1 complex (MEK2 excluded)"],"partners":["MAP2K1","RAF1","ARAF","MAP3K1","USP21","PIN1","RMRP","DLG1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P36507","full_name":"Dual specificity mitogen-activated protein kinase kinase 2","aliases":["ERK activator kinase 2","MAPK/ERK kinase 2","MEK 2"],"length_aa":400,"mass_kda":44.4,"function":"Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126)","subcellular_location":"Cytoplasm; Membrane","url":"https://www.uniprot.org/uniprotkb/P36507/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAP2K2","classification":"Not Classified","n_dependent_lines":48,"n_total_lines":1208,"dependency_fraction":0.039735099337748346},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000126934","cell_line_id":"CID001192","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"MAP2K1","stoichiometry":10.0},{"gene":"YWHAZ","stoichiometry":0.2},{"gene":"YWHAH","stoichiometry":0.2},{"gene":"YWHAE","stoichiometry":0.2},{"gene":"YWHAG","stoichiometry":0.2},{"gene":"ARAF","stoichiometry":0.2},{"gene":"RAF1","stoichiometry":0.2},{"gene":"KSR1","stoichiometry":0.2},{"gene":"YWHAQ","stoichiometry":0.2},{"gene":"YWHAB","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001192","total_profiled":1310},"omim":[{"mim_id":"616850","title":"WD REPEAT-CONTAINING PROTEIN 83; WDR83","url":"https://www.omim.org/entry/616850"},{"mim_id":"615280","title":"CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4","url":"https://www.omim.org/entry/615280"},{"mim_id":"614463","title":"NMYC DOWNSTREAM-REGULATED GENE 4; NDRG4","url":"https://www.omim.org/entry/614463"},{"mim_id":"613754","title":"RING FINGER PROTEIN 187; RNF187","url":"https://www.omim.org/entry/613754"},{"mim_id":"610266","title":"TAO KINASE 1; TAOK1","url":"https://www.omim.org/entry/610266"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MAP2K2"},"hgnc":{"alias_symbol":["MEK2","MKK2"],"prev_symbol":["PRKMK2"]},"alphafold":{"accession":"P36507","domains":[{"cath_id":"3.30.200.20","chopping":"54-147","consensus_level":"high","plddt":92.5152,"start":54,"end":147},{"cath_id":"1.10.510.10","chopping":"152-284_316-386","consensus_level":"high","plddt":92.6786,"start":152,"end":386}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36507","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36507-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36507-F1-predicted_aligned_error_v6.png","plddt_mean":81.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAP2K2","jax_strain_url":"https://www.jax.org/strain/search?query=MAP2K2"},"sequence":{"accession":"P36507","fasta_url":"https://rest.uniprot.org/uniprotkb/P36507.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36507/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36507"}},"corpus_meta":[{"pmid":"15543157","id":"PMC_15543157","title":"Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.","date":"2004","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15543157","citation_count":507,"is_preprint":false},{"pmid":"26399658","id":"PMC_26399658","title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.","date":"2015","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26399658","citation_count":495,"is_preprint":false},{"pmid":"23248257","id":"PMC_23248257","title":"Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.","date":"2012","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23248257","citation_count":403,"is_preprint":false},{"pmid":"22197931","id":"PMC_22197931","title":"Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22197931","citation_count":339,"is_preprint":false},{"pmid":"18982020","id":"PMC_18982020","title":"MEKK1, MKK1/MKK2 and MPK4 function together in a mitogen-activated protein kinase cascade to regulate innate immunity in plants.","date":"2008","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18982020","citation_count":314,"is_preprint":false},{"pmid":"25722381","id":"PMC_25722381","title":"A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.","date":"2015","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25722381","citation_count":298,"is_preprint":false},{"pmid":"8388392","id":"PMC_8388392","title":"Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8388392","citation_count":293,"is_preprint":false},{"pmid":"8386320","id":"PMC_8386320","title":"MKK1 and MKK2, which encode Saccharomyces cerevisiae mitogen-activated protein kinase-kinase homologs, function in the pathway mediated by protein kinase C.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8386320","citation_count":274,"is_preprint":false},{"pmid":"7671816","id":"PMC_7671816","title":"Three genes of the MAP kinase cascade, mek-2, mpk-1/sur-1 and let-60 ras, are required for meiotic cell cycle progression in Caenorhabditis elegans.","date":"1995","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/7671816","citation_count":257,"is_preprint":false},{"pmid":"17116858","id":"PMC_17116858","title":"Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17116858","citation_count":233,"is_preprint":false},{"pmid":"10417144","id":"PMC_10417144","title":"Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway.","date":"1999","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10417144","citation_count":212,"is_preprint":false},{"pmid":"24122251","id":"PMC_24122251","title":"IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.","date":"2014","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24122251","citation_count":179,"is_preprint":false},{"pmid":"7565670","id":"PMC_7565670","title":"A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565670","citation_count":174,"is_preprint":false},{"pmid":"7624324","id":"PMC_7624324","title":"MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7624324","citation_count":158,"is_preprint":false},{"pmid":"24055054","id":"PMC_24055054","title":"Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24055054","citation_count":153,"is_preprint":false},{"pmid":"12832465","id":"PMC_12832465","title":"Mek2 is dispensable for mouse growth and development.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12832465","citation_count":146,"is_preprint":false},{"pmid":"8393135","id":"PMC_8393135","title":"Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8393135","citation_count":139,"is_preprint":false},{"pmid":"19219045","id":"PMC_19219045","title":"A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.","date":"2009","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19219045","citation_count":139,"is_preprint":false},{"pmid":"7969158","id":"PMC_7969158","title":"RAS and RAF-1 form a signalling complex with MEK-1 but not MEK-2.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7969158","citation_count":110,"is_preprint":false},{"pmid":"8621729","id":"PMC_8621729","title":"Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621729","citation_count":107,"is_preprint":false},{"pmid":"15284233","id":"PMC_15284233","title":"MEK1 and MEK2, different regulators of the G1/S transition.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15284233","citation_count":97,"is_preprint":false},{"pmid":"7729690","id":"PMC_7729690","title":"MEK-2, a Caenorhabditis elegans MAP kinase kinase, functions in Ras-mediated vulval induction and other developmental events.","date":"1995","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7729690","citation_count":88,"is_preprint":false},{"pmid":"7729691","id":"PMC_7729691","title":"The Caenorhabditis elegans gene mek-2 is required for vulval induction and encodes a protein similar to the protein kinase MEK.","date":"1995","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7729691","citation_count":82,"is_preprint":false},{"pmid":"18060073","id":"PMC_18060073","title":"Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18060073","citation_count":74,"is_preprint":false},{"pmid":"19156172","id":"PMC_19156172","title":"Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19156172","citation_count":67,"is_preprint":false},{"pmid":"29706623","id":"PMC_29706623","title":"The deubiquitinase USP21 stabilizes MEK2 to promote tumor growth.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29706623","citation_count":66,"is_preprint":false},{"pmid":"30998777","id":"PMC_30998777","title":"βC1 protein encoded in geminivirus satellite concertedly targets MKK2 and MPK4 to counter host defense.","date":"2019","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/30998777","citation_count":61,"is_preprint":false},{"pmid":"8626767","id":"PMC_8626767","title":"Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626767","citation_count":61,"is_preprint":false},{"pmid":"28933595","id":"PMC_28933595","title":"Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy.","date":"2017","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/28933595","citation_count":55,"is_preprint":false},{"pmid":"8297798","id":"PMC_8297798","title":"MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues.","date":"1993","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/8297798","citation_count":55,"is_preprint":false},{"pmid":"19014680","id":"PMC_19014680","title":"Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19014680","citation_count":55,"is_preprint":false},{"pmid":"19304888","id":"PMC_19304888","title":"Map2k1 and Map2k2 genes contribute to the normal development of syncytiotrophoblasts during placentation.","date":"2009","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19304888","citation_count":51,"is_preprint":false},{"pmid":"11748628","id":"PMC_11748628","title":"Estradiol-induced phosphorylation of ERK1/2 in explants of the mouse cerebral cortex: the roles of heat shock protein 90 (Hsp90) and MEK2.","date":"2002","source":"Journal of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/11748628","citation_count":50,"is_preprint":false},{"pmid":"30590768","id":"PMC_30590768","title":"Disruption of the MAMP-Induced MEKK1-MKK1/MKK2-MPK4 Pathway Activates the TNL Immune Receptor SMN1/RPS6.","date":"2019","source":"Plant & cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30590768","citation_count":45,"is_preprint":false},{"pmid":"9328344","id":"PMC_9328344","title":"Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism.","date":"1997","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9328344","citation_count":45,"is_preprint":false},{"pmid":"19383924","id":"PMC_19383924","title":"Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19383924","citation_count":45,"is_preprint":false},{"pmid":"14670079","id":"PMC_14670079","title":"Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/14670079","citation_count":43,"is_preprint":false},{"pmid":"17928366","id":"PMC_17928366","title":"MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17928366","citation_count":40,"is_preprint":false},{"pmid":"8702863","id":"PMC_8702863","title":"Chemotactic peptide-induced activation of MEK-2, the predominant isoform in human neutrophils. Inhibition by wortmannin.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702863","citation_count":40,"is_preprint":false},{"pmid":"24746703","id":"PMC_24746703","title":"Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24746703","citation_count":39,"is_preprint":false},{"pmid":"18657070","id":"PMC_18657070","title":"Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis.","date":"2008","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/18657070","citation_count":39,"is_preprint":false},{"pmid":"34183010","id":"PMC_34183010","title":"Myc-associated zinc-finger protein promotes clear cell renal cell carcinoma progression through transcriptional activation of the MAP2K2-dependent ERK pathway.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34183010","citation_count":38,"is_preprint":false},{"pmid":"35075244","id":"PMC_35075244","title":"YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35075244","citation_count":37,"is_preprint":false},{"pmid":"33405090","id":"PMC_33405090","title":"Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma.","date":"2021","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/33405090","citation_count":36,"is_preprint":false},{"pmid":"17711850","id":"PMC_17711850","title":"Retrophosphorylation of Mkk1 and Mkk2 MAPKKs by the Slt2 MAPK in the yeast cell integrity pathway.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17711850","citation_count":35,"is_preprint":false},{"pmid":"8596433","id":"PMC_8596433","title":"Characterization of domains in the yeast MAP kinase Slt2 (Mpk1) required for functional activity and in vivo interaction with protein kinases Mkk1 and Mkk2.","date":"1995","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/8596433","citation_count":35,"is_preprint":false},{"pmid":"20358587","id":"PMC_20358587","title":"Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20358587","citation_count":34,"is_preprint":false},{"pmid":"21610019","id":"PMC_21610019","title":"Two mitogen-activated protein kinase kinases, MKK1 and MEK2, are involved in wounding- and specialist lepidopteran herbivore Manduca sexta-induced responses in Nicotiana attenuata.","date":"2011","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/21610019","citation_count":33,"is_preprint":false},{"pmid":"26814233","id":"PMC_26814233","title":"Functional redundancy of the kinases MEK1 and MEK2: Rescue of the Mek1 mutant phenotype by Mek2 knock-in reveals a protein threshold effect.","date":"2016","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26814233","citation_count":33,"is_preprint":false},{"pmid":"28106078","id":"PMC_28106078","title":"Comparative Phosphoproteomics Reveals an Important Role of MKK2 in Banana (Musa spp.) Cold Signal Network.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28106078","citation_count":30,"is_preprint":false},{"pmid":"23379592","id":"PMC_23379592","title":"Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?","date":"2013","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23379592","citation_count":28,"is_preprint":false},{"pmid":"20172001","id":"PMC_20172001","title":"Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2.","date":"2010","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/20172001","citation_count":28,"is_preprint":false},{"pmid":"27181679","id":"PMC_27181679","title":"MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27181679","citation_count":26,"is_preprint":false},{"pmid":"26197240","id":"PMC_26197240","title":"The Mkk2 MAPKK Regulates Cell Wall Biogenesis in Cooperation with the Cek1-Pathway in Candida albicans.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26197240","citation_count":24,"is_preprint":false},{"pmid":"33226073","id":"PMC_33226073","title":"O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells.","date":"2021","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33226073","citation_count":24,"is_preprint":false},{"pmid":"20179103","id":"PMC_20179103","title":"Active Mek2 as a regulatory scaffold that promotes Pin1 binding to BPGAP1 to suppress BPGAP1-induced acute Erk activation and cell migration.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/20179103","citation_count":22,"is_preprint":false},{"pmid":"21365009","id":"PMC_21365009","title":"MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21365009","citation_count":21,"is_preprint":false},{"pmid":"9121773","id":"PMC_9121773","title":"Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9121773","citation_count":21,"is_preprint":false},{"pmid":"20514469","id":"PMC_20514469","title":"MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells.","date":"2010","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20514469","citation_count":20,"is_preprint":false},{"pmid":"31901897","id":"PMC_31901897","title":"Lycorine Induces autophagy-associated apoptosis by targeting MEK2 and enhances vemurafenib activity in colorectal cancer.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31901897","citation_count":20,"is_preprint":false},{"pmid":"31562895","id":"PMC_31562895","title":"Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059.","date":"2019","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/31562895","citation_count":20,"is_preprint":false},{"pmid":"33908440","id":"PMC_33908440","title":"Genistein suppresses allergic contact dermatitis through regulating the MAP2K2/ERK pathway.","date":"2021","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/33908440","citation_count":18,"is_preprint":false},{"pmid":"9149902","id":"PMC_9149902","title":"Differential expression of MEK1 and MEK2 during mouse development.","date":"1997","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9149902","citation_count":18,"is_preprint":false},{"pmid":"36689133","id":"PMC_36689133","title":"Lnc_000048 Promotes Histone H3K4 Methylation of MAP2K2 to Reduce Plaque Stability by Recruiting KDM1A in Carotid Atherosclerosis.","date":"2023","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36689133","citation_count":16,"is_preprint":false},{"pmid":"23735655","id":"PMC_23735655","title":"MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.","date":"2013","source":"Physical biology","url":"https://pubmed.ncbi.nlm.nih.gov/23735655","citation_count":16,"is_preprint":false},{"pmid":"12608905","id":"PMC_12608905","title":"Basic fibroblast growth factor induces the expression of matrix metalloproteinase-3 in human periodontal ligament cells through the MEK2 mitogen-activated protein kinase pathway.","date":"2003","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/12608905","citation_count":15,"is_preprint":false},{"pmid":"26793709","id":"PMC_26793709","title":"The TAK1→IKKβ→TPL2→MKK1/MKK2 Signaling Cascade Regulates IL-33 Expression in Cystic Fibrosis Airway Epithelial Cells Following Infection by Pseudomonas aeruginosa.","date":"2016","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26793709","citation_count":15,"is_preprint":false},{"pmid":"12784909","id":"PMC_12784909","title":"Inhibition of CCL11, CCL24, and CCL26-induced degranulation in HL-60 eosinophilic cells by specific inhibitors of MEK1/MEK2, p38 MAP kinase, and PI 3-kinase.","date":"2003","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/12784909","citation_count":14,"is_preprint":false},{"pmid":"22561024","id":"PMC_22561024","title":"Implication of MEK1 and MEK2 in the establishment of the blood-placenta barrier during placentogenesis in mouse.","date":"2012","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/22561024","citation_count":12,"is_preprint":false},{"pmid":"20837746","id":"PMC_20837746","title":"A novel MEK2/PI3Kδ pathway controls the expression of IL-1 receptor antagonist in IFN-β-activated human monocytes.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20837746","citation_count":12,"is_preprint":false},{"pmid":"34935273","id":"PMC_34935273","title":"The Raf-like kinase Raf36 negatively regulates plant resistance against the oomycete pathogen Phytophthora parasitica by targeting MKK2.","date":"2021","source":"Molecular plant pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34935273","citation_count":11,"is_preprint":false},{"pmid":"22185284","id":"PMC_22185284","title":"The MEK2-binding tumor suppressor hDlg is recruited by E-cadherin to the midbody ring.","date":"2011","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22185284","citation_count":11,"is_preprint":false},{"pmid":"37493364","id":"PMC_37493364","title":"PhyB-dependent phosphorylation of mitogen-activated protein kinase cascade MKK2-MPK2 positively regulates red light-induced stomatal opening.","date":"2023","source":"Plant, cell & environment","url":"https://pubmed.ncbi.nlm.nih.gov/37493364","citation_count":10,"is_preprint":false},{"pmid":"30710049","id":"PMC_30710049","title":"MEK2 Negatively Regulates Lipopolysaccharide-Mediated IL-1β Production through HIF-1α Expression.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30710049","citation_count":10,"is_preprint":false},{"pmid":"38695657","id":"PMC_38695657","title":"Soybean MKK2 establishes intricate signalling pathways to regulate soybean response to cyst nematode infection.","date":"2024","source":"Molecular plant pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38695657","citation_count":10,"is_preprint":false},{"pmid":"27301426","id":"PMC_27301426","title":"Interaction of tRNA with MEK2 in pancreatic cancer cells.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27301426","citation_count":10,"is_preprint":false},{"pmid":"21509657","id":"PMC_21509657","title":"A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).","date":"2011","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21509657","citation_count":10,"is_preprint":false},{"pmid":"29799162","id":"PMC_29799162","title":"MAP2K2 mutation as a cause of cardio-facio-cutaneous syndrome in an infant with a severe and fatal course of the disease.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/29799162","citation_count":9,"is_preprint":false},{"pmid":"31907980","id":"PMC_31907980","title":"MEK2 is a critical modulating mechanism to down-regulate GCIP stability and function in cancer cells.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31907980","citation_count":9,"is_preprint":false},{"pmid":"22895183","id":"PMC_22895183","title":"MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22895183","citation_count":9,"is_preprint":false},{"pmid":"36901876","id":"PMC_36901876","title":"Investigating a Library of Flavonoids as Potential Inhibitors of a Cancer Therapeutic Target MEK2 Using in Silico Methods.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36901876","citation_count":8,"is_preprint":false},{"pmid":"24311457","id":"PMC_24311457","title":"Multiple café au lait spots in familial patients with MAP2K2 mutation.","date":"2013","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/24311457","citation_count":7,"is_preprint":false},{"pmid":"35157553","id":"PMC_35157553","title":"MAP2K2 Delays Recovery in Murine Models of Acute Lung Injury and Associates with Acute Respiratory Distress Syndrome Outcome.","date":"2022","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35157553","citation_count":7,"is_preprint":false},{"pmid":"34386488","id":"PMC_34386488","title":"Mek1 and Mek2 Functional Redundancy in Erythropoiesis.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34386488","citation_count":6,"is_preprint":false},{"pmid":"25487361","id":"PMC_25487361","title":"Familial cardiofaciocutaneous syndrome in a father and a son with a novel MEK2 mutation.","date":"2014","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25487361","citation_count":6,"is_preprint":false},{"pmid":"39781472","id":"PMC_39781472","title":"The positive feedback loop between SP1 and MAP2K2 significantly drives resistance to VEGFR inhibitors in clear cell renal cell carcinoma.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39781472","citation_count":5,"is_preprint":false},{"pmid":"35762548","id":"PMC_35762548","title":"The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis.","date":"2023","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35762548","citation_count":5,"is_preprint":false},{"pmid":"38193111","id":"PMC_38193111","title":"Circular RNA MAP2K2-modified immunosuppressive dendritic cells for preventing alloimmune rejection in organ transplantation.","date":"2023","source":"Bioengineering & translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38193111","citation_count":5,"is_preprint":false},{"pmid":"10828601","id":"PMC_10828601","title":"Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.","date":"2000","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10828601","citation_count":5,"is_preprint":false},{"pmid":"34209498","id":"PMC_34209498","title":"A Heterozygous Missense Variant in MAP2K2 in a Stillborn Romagnola Calf with Skeletal-Cardio-Enteric Dysplasia.","date":"2021","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/34209498","citation_count":5,"is_preprint":false},{"pmid":"26572230","id":"PMC_26572230","title":"Activation of MEK2 is sufficient to induce skin papilloma formation in transgenic zebrafish.","date":"2015","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/26572230","citation_count":5,"is_preprint":false},{"pmid":"27751966","id":"PMC_27751966","title":"Concurrent occurrence of an inherited 16p13.11 microduplication and a de novo 19p13.3 microdeletion involving MAP2K2 in a patient with developmental delay, distinctive facial features, and lambdoid synostosis.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27751966","citation_count":5,"is_preprint":false},{"pmid":"23217386","id":"PMC_23217386","title":"MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.","date":"2012","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23217386","citation_count":4,"is_preprint":false},{"pmid":"38259097","id":"PMC_38259097","title":"Lung Fibroblasts Take up Breast Cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38259097","citation_count":4,"is_preprint":false},{"pmid":"9398267","id":"PMC_9398267","title":"Cloning and characterization of cDNAs encoding chicken mitogen-activated protein kinase kinase type 2, MEK2: downregulation of MEK2 in response to inhibition of mitochondrial DNA expression.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9398267","citation_count":4,"is_preprint":false},{"pmid":"39438862","id":"PMC_39438862","title":"Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39438862","citation_count":3,"is_preprint":false},{"pmid":"38798178","id":"PMC_38798178","title":"MicroRNA-2285f regulates milk fat metabolism by targeting MAP2K2 in bovine mammary epithelial cells.","date":"2024","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/38798178","citation_count":3,"is_preprint":false},{"pmid":"30419398","id":"PMC_30419398","title":"Characterization and functional analysis of grouper (Epinephelus coioides) MEK1 and MEK2.","date":"2018","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30419398","citation_count":3,"is_preprint":false},{"pmid":"11909642","id":"PMC_11909642","title":"Identification of interaction between MEK2 and A-Raf-1.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11909642","citation_count":3,"is_preprint":false},{"pmid":"32800341","id":"PMC_32800341","title":"Expression of kinase-deficient MEK2 ameliorates Pelizaeus-Merzbacher disease phenotypes in mice.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32800341","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50843,"output_tokens":7528,"usd":0.132724,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16888,"output_tokens":4323,"usd":0.096257,"stage2_stop_reason":"end_turn"},"total_usd":0.228981,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structures of human MEK1 and MEK2 each determined as ternary complexes with MgATP and an inhibitor reveal a unique allosteric inhibitor-binding pocket adjacent to the ATP-binding site. The inhibitor induces conformational changes that lock unphosphorylated MEK1 and MEK2 into a closed but catalytically inactive species, establishing a noncompetitive mechanism for kinase inhibition.\",\n      \"method\": \"X-ray crystallography (2.4 Å for MEK1, 3.2 Å for MEK2)\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with functional validation, two isoforms solved, established novel mechanism\",\n      \"pmids\": [\"15543157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Human MEK2 was cloned and shown to be a dual-specificity kinase that phosphorylates ERK1 on both threonine and tyrosine residues, activating ERK1 kinase activity more than 100-fold in vitro. Recombinant MEK2 can be activated by serum-stimulated cell extract in vitro.\",\n      \"method\": \"In vitro kinase assay with recombinant proteins expressed in E. coli\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution of enzymatic activity, replicated by multiple independent cloning papers in same year\",\n      \"pmids\": [\"8388392\", \"8393135\", \"8297798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"MEK2 (MKK2) can be phosphorylated and activated by v-Raf in vitro, and both MEK1 and MEK2 are activated in vivo in response to serum, establishing Raf as an upstream activator of MEK2.\",\n      \"method\": \"In vitro kinase assay; in vivo activation assay in COS cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro phosphorylation assay plus in vivo confirmation, replicated across multiple early studies\",\n      \"pmids\": [\"8393135\", \"8388392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MEKK1 catalytic domain phosphorylates MEK1 and MEK2 activation-loop serines (S218/S222 equivalents) in vitro and interacts with MEK1 in the two-hybrid system. Expression of MEKK1 in mammalian cells causes constitutive activation of both MEK1 and MEK2, although downstream ERK2 activation is modest compared to EGF stimulation.\",\n      \"method\": \"In vitro kinase assay, yeast two-hybrid, transfection in mammalian cells with Western blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (in vitro assay, two-hybrid, cell-based activation), identified phosphorylation sites\",\n      \"pmids\": [\"7624324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A proline-rich (PR) sequence unique to MEK1 and MEK2 is required for Raf family binding and MEK activation. Deletion of the PR sequence from MEK1 blocked association with Raf and markedly attenuated growth factor-induced activation. A phosphorylation site within the PR sequence of MEK1 sustains activity, whereas MEK2 lacks this site and shows only transient activation after serum stimulation.\",\n      \"method\": \"Deletion mutagenesis, co-immunoprecipitation, in vivo kinase assays in fibroblasts\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple mutants tested, reciprocal interaction experiments, functional readout of transformation\",\n      \"pmids\": [\"7565670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"RAS and RAF-1 form a signaling complex with MEK1 but not MEK2. MEK-2 was not detected in the RAS:RAF-1:MEK-1 complex, and consistent with this, basal MEK2 activity in v-ras-transformed cells was elevated only twofold vs. sixfold for MEK1, indicating differential coupling of MEK1 and MEK2 to the RAS signaling complex.\",\n      \"method\": \"Immobilized RAS pulldown, co-immunoprecipitation from cell lysates, kinase activity assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal pulldown and activity measurements, finding replicated in selectivity literature\",\n      \"pmids\": [\"7969158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A-Raf selectively phosphorylates and activates MEK1 but not MEK2 upon EGF stimulation of HeLa cells, whereas c-Raf activates both MEK1 and MEK2. Using MEK1-S218/222A as bait in yeast two-hybrid screens, all three Raf isoforms were identified as MEK1 interactors.\",\n      \"method\": \"Yeast two-hybrid screening, in vitro kinase assay, EGF stimulation of HeLa cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — yeast two-hybrid plus in vitro kinase assay, isoform-selective result\",\n      \"pmids\": [\"8621729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The Yersinia effector YopJ acetylates two serine residues in the activation loop of MEK2, preventing their phosphorylation required for MEK2 activation. This covalent acetylation is the mechanism by which YopJ blocks MAPK signaling.\",\n      \"method\": \"Mass spectrometry-based identification of acetylation sites, biochemical inhibition assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — novel covalent modification characterized by MS with functional consequence, single lab but clear mechanistic readout\",\n      \"pmids\": [\"17116858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MEK1 and MEK2 form a heterodimer in which MEK1 downregulates MEK2-dependent ERK signaling. ERK phosphorylates MEK1 at Thr292 (a residue absent in MEK2), creating a negative feedback that also reduces MEK2 phosphorylation within the heterodimer. Loss of MEK1 stabilizes MEK2 phosphorylation and sustains ERK activation in cultured cells and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, phospho-specific Western blot, MEK1 knockout mouse embryos, site-directed mutagenesis of Thr292\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP establishing heterodimer, mutagenesis of feedback site, in vivo confirmation in KO mice, multiple orthogonal methods\",\n      \"pmids\": [\"19219045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MEK1-activated ERK2 accumulates in the nucleus and promotes proliferation, whereas MEK2-activated ERK2 is retained in the cytoplasm and supports cell survival. MEK1-mediated nuclear translocation of ERK2 depends on phosphorylation of MEK1 residues S298 (by PAK) and T292 (by ERK2 feedback), sites present in MEK1 but not MEK2.\",\n      \"method\": \"siRNA knockdown, nuclear export sequence constructs, immunofluorescence/subcellular fractionation, phospho-site mutagenesis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (siRNA, localization, mutagenesis), isoform-specific localization with functional consequence\",\n      \"pmids\": [\"17928366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Upon EGF receptor activation, a pool of MEK2 is recruited to the plasma membrane and then to early and late endosomes via clathrin-dependent endocytosis. RAF kinase activity and MEK catalytic activity are required for endosomal targeting of MEK2. Clathrin knockdown abolishes MEK2 endosomal recruitment and increases ERK activation, suggesting endosomal MEK2 participates in negative feedback regulation.\",\n      \"method\": \"GFP-tagged MEK2 live imaging, siRNA knockdown of clathrin and RAF, fluorescence microscopy in HeLa cells\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live-cell imaging with GFP-MEK2, siRNA knockdowns, functional ERK readout, multiple perturbations\",\n      \"pmids\": [\"18657070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The deubiquitinase USP21 stabilizes MEK2 by removing Lys48-linked polyubiquitin chains from MEK2, preventing its proteasomal degradation and thereby sustaining ERK signaling.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, ectopic expression in cell lines\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and ubiquitination assay in single lab, mechanistic site (K48 linkage) identified but mutagenesis of specific ubiquitin sites not described in abstract\",\n      \"pmids\": [\"29706623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The small GTPase RBJ interacts with MEK1/MEK2 in the nucleus, prolongs MEK/ERK activation by nuclear entrapment, and promotes carcinogenesis. RBJ deficiency abrogates nuclear accumulation of MEK1/MEK2 and attenuates ERK1/ERK2 activation.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, RBJ knockout mouse model, tumor model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, fractionation, in vivo KO model, single lab\",\n      \"pmids\": [\"24746703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Active MEK2 (but not kinase-dead MEK2) serves as a scaffold that bridges Pin1 and BPGAP1, promoting Pin1 binding to BPGAP1 to suppress acute ERK activation and cell migration. Only catalytically active MEK2 can bind Pin1, and this interaction requires release of an autoinhibited proline-rich motif in BPGAP1.\",\n      \"method\": \"Co-immunoprecipitation, kinase-dead and constitutively active MEK2 mutants, siRNA knockdown, cell migration assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with active vs kinase-dead mutants, functional readout, single lab\",\n      \"pmids\": [\"20179103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The human Discs-large tumor suppressor hDlg interacts with the phosphorylated (active) form of MEK2 at the midbody ring during cytokinesis. The interaction depends on MEK2 phosphorylation and is mediated by the PDZ domains of hDlg binding the C-terminal portion of MEK2. E-cadherin expression is required for isoform-specific recruitment of hDlg (but not active MEK2) to the midbody.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, cell cycle synchronization, E-cadherin knockdown\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, localization, E-cadherin dependency test; single lab\",\n      \"pmids\": [\"22185284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MEK2 directly interacts with and phosphorylates the tumor suppressor GCIP at Ser313 and Ser356, promoting ubiquitin-mediated proteasomal degradation of GCIP and enhancing cancer cell proliferation and migration.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phospho-site mutagenesis, ubiquitination assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation with site mutagenesis plus ubiquitination/degradation readout, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"31907980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MEK2 physically interacts with ribonucleotide reductase small subunit p53R2 and upregulates RNR enzymatic activity. The MEK2 segment comprising amino acids 65–171 is critical for p53R2-MEK2 interaction. Ionizing radiation augments MEK2 phosphorylation and concurrently increases RNR activity in a MEK2-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, deletion mapping, MEK inhibitor treatment, siRNA knockdown, RNR activity assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, activity assay, siRNA confirmation; single lab\",\n      \"pmids\": [\"22895183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MEK2 is O-GlcNAcylated at Thr13 by OGT. O-GlcNAcylation at Thr13 (located in the docking domain) enhances MEK2 Thr394 phosphorylation and downstream ERK1/2 activation. Ablation of Thr13 O-GlcNAcylation abolishes MEK2-driven proliferation and migration of breast cancer cells.\",\n      \"method\": \"Mass spectrometry identification of O-GlcNAc site, site-directed mutagenesis, Western blot, cell proliferation/migration assay\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS identification of modification site, mutagenesis, functional readout; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"33226073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A-Raf interacts with MEK2 through its kinase domain (residues 255–606), as identified by yeast two-hybrid screening and confirmed by in vitro binding assay.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Weak — yeast two-hybrid plus in vitro pulldown, but single lab and no functional phosphorylation readout for MEK2\",\n      \"pmids\": [\"11909642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MEK2 is the predominant MEK isoform activated in human neutrophils by chemotactic peptides, with activity at least 3-fold greater than MEK1. MEK2 activation is more sensitive to the PI3-kinase inhibitor wortmannin than MEK1, indicating differential upstream regulation, and both isoforms are activated by PKC agonists.\",\n      \"method\": \"Immunoprecipitation kinase assay, pharmacological inhibition, fMLP stimulation of primary neutrophils\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — isoform-specific immunoprecipitation kinase assays, multiple inhibitors tested; single study\",\n      \"pmids\": [\"8702863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MEK2, but not MEK1, controls MKK3/MKK6-p38 MAPK axis phosphorylation in MDA-MB-231 breast cancer cells independent of ERK1/2 activation. MEK2 silencing decreases cyclin D1 expression and increases apoptosis, while MEK1 silencing has the opposite effect.\",\n      \"method\": \"siRNA knockdown of MEK1 and MEK2 individually, Western blot for p38, MKK3/6 phosphorylation, cell viability assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — isoform-specific siRNA with phosphoprotein readout, unexpected non-ERK pathway identified; single lab\",\n      \"pmids\": [\"27181679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MEK2 acts upstream of PI3Kδ in IFN-β-stimulated human monocytes to regulate IL-1Ra production. Blockade of MEK2 (but not MEK1) prevented PI3Kδ membrane recruitment, Akt phosphorylation, and IL-1Ra production. ERK1/2 are dispensable for this pathway, suggesting a non-canonical MEK2 signaling function.\",\n      \"method\": \"MEK isoform-selective inhibitors, siRNA knockdown, subcellular fractionation, immunoprecipitation in primary human monocytes\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA plus pharmacological inhibition with membrane fractionation; novel pathway but single lab\",\n      \"pmids\": [\"20837746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MEK2 inversely and independently regulates HIF-1α expression and IL-1β production in LPS-stimulated macrophages. MEK2-deficient bone marrow-derived macrophages show preserved ERK1/2 phosphorylation but higher HIF-1α, Glut1, and IL-1β levels. Overexpression of MEK2 in RAW264.7 cells decreases IL-1β production after LPS stimulation, establishing MEK2 as a negative regulator of HIF-1α/IL-1β independent of ERK.\",\n      \"method\": \"MEK2 knockout macrophages, siRNA knockdown of HIF-1α, MEK2 overexpression, Western blot, cytokine ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse-derived macrophages plus gain-of-function, siRNA epistasis; single lab with multiple approaches\",\n      \"pmids\": [\"30710049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRNA interacts with MEK2 in pancreatic cancer cells, and the MEK2 inhibitor U0126 significantly reduces the tRNA-MEK2 interaction. tRNA modulates MEK2 catalytic activity differently for wild-type and cancer-associated mutant forms (Q60P, P128Q, S154F, E207K).\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase activity assay, MEK2 mutant constructs\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and activity assay, unusual finding not replicated, single lab\",\n      \"pmids\": [\"27301426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mek2-null mice are viable and fertile with no overt morphological defects, demonstrating that MEK2 is dispensable for normal mouse development and that its loss is compensated by MEK1.\",\n      \"method\": \"Gene targeting (knockout mouse), phenotypic analysis including thymocyte development and T-cell proliferation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean germline knockout with comprehensive phenotypic analysis\",\n      \"pmids\": [\"12832465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Map2k2 haploinsufficiency in combination with one null Map2k1 allele causes placental defects restricted to extra-embryonic tissues and embryonic lethality. The severity correlates with total MEK protein levels regardless of isoform identity, indicating a dosage threshold effect for placental development.\",\n      \"method\": \"Compound mutant mouse genetics (allelic series), conditional Map2k1 deletion, histological analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic allelic series in vivo, tissue-specific rescue experiments\",\n      \"pmids\": [\"19304888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MEK1 and MEK2 are functionally redundant at the protein level: knock-in of Mek2 coding sequences under Mek1 regulatory control rescues Mek1-null lethality, establishing that the embryonic phenotype reflects protein quantity rather than isoform-specific biochemistry.\",\n      \"method\": \"Knock-in mouse genetics, allelic series analysis, embryo viability assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous knock-in rescue experiment in vivo demonstrating functional redundancy\",\n      \"pmids\": [\"26814233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MAP2K2 (MEK2) in myeloid/leukocyte cells delays resolution of acute lung injury. Mek2-/- mice show faster resolution of alveolar neutrophilia and vascular leak following Pseudomonas aeruginosa injury. Bone marrow chimera studies confirm leukocyte MAP2K2 as the key regulator of ALI duration.\",\n      \"method\": \"Mek2-null mouse model, bone marrow chimera, acute lung injury models, gene expression analysis\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with bone marrow chimera to define cell compartment, single lab\",\n      \"pmids\": [\"35157553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ERK1 residues flanking its regulatory phosphorylation sites determine specificity of recognition and phosphorylation by MEK1 and MEK2. Mutation of Arg-208 dramatically increases tyrosine phosphorylation while eliminating threonine phosphorylation; mutation of Gly-199 increases threonine vs. tyrosine phosphorylation, demonstrating that the phosphorylation lip of ERK is a determinant of MEK substrate recognition.\",\n      \"method\": \"Site-directed mutagenesis of ERK1, in vitro phosphorylation assay with MEK1 and MEK2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with in vitro phosphorylation assay, multiple mutants tested, single lab\",\n      \"pmids\": [\"8626767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MEK2 is sufficient to sustain ERK activation, proliferation, and anchorage-independent growth of SK-MEL-28 melanoma cells when other MKKs are cleaved by anthrax lethal toxin. MEK1 and MEK2 drive non-overlapping downstream transcriptional programs in these cells.\",\n      \"method\": \"Anthrax lethal toxin MEK cleavage, protease-resistant MEK mutants (MEK1cr, MEK2cr), microarray transcriptomics, proliferation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — elegant gain-of-function experimental design with protease-resistant mutants, microarray readout; single lab\",\n      \"pmids\": [\"21365009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In Pelizaeus-Merzbacher disease model mice, oligodendrocyte-specific expression of a kinase-deficient dominant-inhibitory MEK2 mutant (MEK2K101A) promotes CNS myelination and improves motor coordination, establishing that MEK2 signaling suppresses oligodendrocyte differentiation and myelination.\",\n      \"method\": \"Transgenic mouse expressing kinase-dead MEK2K101A in oligodendrocytes, histological myelination analysis, Rotarod behavioral testing\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo transgenic approach with functional behavioral readout, but single lab and single method\",\n      \"pmids\": [\"32800341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MEK2, but not MEK1, mediates uptake of breast cancer cell-derived extracellular vesicles by lung fibroblasts through a macropinocytosis mechanism. Gene knockdown and overexpression studies established MEK2 as required for this process.\",\n      \"method\": \"siRNA knockdown, MEK2 overexpression, high-content microscopy, macropinocytosis assay\",\n      \"journal\": \"Cancer research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — loss-of-function and gain-of-function with defined cellular readout; single lab\",\n      \"pmids\": [\"38259097\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAP2K2 (MEK2) is a dual-specificity kinase that phosphorylates ERK1/2 on both threonine and tyrosine residues to activate them; it is structurally characterized by a unique allosteric inhibitor pocket that locks the enzyme in a catalytically inactive conformation, is activated by Raf-family kinases (c-Raf, B-Raf) and MEKK1 via activation-loop serine phosphorylation, forms a heterodimer with MEK1 through which ERK-mediated feedback phosphorylation of MEK1-Thr292 indirectly dampens MEK2 activity, and undergoes additional post-translational regulation including activation-loop acetylation by bacterial YopJ, O-GlcNAcylation at Thr13 that enhances activity, and Lys48-linked polyubiquitination reversed by USP21; subcellularly, MEK2 is recruited to endosomes in a RAF- and clathrin-dependent manner as part of negative feedback, is retained in the nucleus by the small GTPase RBJ to prolong ERK signaling, and directs ERK2 to the cytoplasm for survival rather than the nucleus for proliferation; beyond ERK, MEK2 engages non-canonical substrates including p53R2/RNR, GCIP, and the PI3Kδ pathway, and plays essential roles in placental development and erythropoiesis in a dosage-dependent manner with MEK1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MAP2K2 (MEK2) is a dual-specificity protein kinase that phosphorylates ERK1/2 on both threonine and tyrosine within their activation lip, switching them on more than 100-fold and thereby relaying RAS-RAF signaling to the ERK MAP kinase cascade [#1, #28]. It is activated through phosphorylation of two activation-loop serines by Raf-family kinases (c-Raf, v-Raf) and by MEKK1, with c-Raf engaging MEK2 while A-Raf selectively favors MEK1 [#2, #3, #6]. Crystal structures of MEK2 reveal a unique allosteric pocket adjacent to the ATP site where inhibitors lock the unphosphorylated enzyme in a closed, catalytically inactive conformation, defining a noncompetitive inhibition mechanism [#0]. MEK2 activity is further tuned by post-translational modifications: O-GlcNAcylation at Thr13 by OGT enhances activation-loop phosphorylation and downstream ERK signaling [#17], USP21 removes Lys48-linked polyubiquitin to stabilize MEK2 and sustain ERK output [#11], and the bacterial effector YopJ acetylates the activation-loop serines to block phosphorylation and shut down signaling [#7]. MEK2 functions in dynamic balance with MEK1: the two form a heterodimer in which ERK feedback phosphorylation of the MEK1-specific Thr292 dampens MEK2 phosphorylation, and MEK2-activated ERK2 is biased toward cytoplasmic retention and survival rather than the nuclear, proliferative output driven by MEK1 [#8, #9]. Beyond canonical ERK activation, MEK2 phosphorylates the tumor suppressor GCIP to drive its degradation [#15], scaffolds Pin1–BPGAP1 complexes to restrain ERK activation and migration [#13], regulates ribonucleotide reductase via p53R2 binding [#16], and acts through ERK-independent routes on the MKK3/6–p38 axis and the PI3Kδ–IL-1Ra pathway [#20, #21]. Genetically, MEK2 is dispensable for normal mouse development because MEK1 compensates, yet combined MEK dosage below a threshold causes placental defects and embryonic lethality, and isoform swapping shows MEK1 and MEK2 are functionally redundant at the protein level [#24, #25, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the core enzymatic identity of MEK2 as a dual-specificity kinase that activates ERK, answering what biochemical step MEK2 performs in the cascade.\",\n      \"evidence\": \"in vitro kinase assays with recombinant MEK2 phosphorylating ERK1 on Thr and Tyr\",\n      \"pmids\": [\"8388392\", \"8393135\", \"8297798\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define upstream activators in cells\", \"Did not address MEK1 vs MEK2 functional divergence\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Placed MEK2 downstream of Raf, defining the canonical RAS-RAF-MEK-ERK linkage for this isoform.\",\n      \"evidence\": \"in vitro phosphorylation by v-Raf and serum-induced in vivo activation in COS cells\",\n      \"pmids\": [\"8393135\", \"8388392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Raf isoform selectivity not resolved\", \"Activation-loop phosphosites not yet mapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identified MEKK1 as an additional activator and mapped activation-loop serines as the activating sites, clarifying how MEK2 is switched on.\",\n      \"evidence\": \"in vitro kinase assay, yeast two-hybrid, and mammalian cell activation\",\n      \"pmids\": [\"7624324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological versus overexpression contribution of MEKK1 unclear\", \"ERK activation by MEKK1 was modest\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Revealed isoform-selective upstream coupling — c-Raf activates both MEK1/MEK2 while A-Raf and the RAS:RAF complex favor MEK1 — beginning the distinction between the two MEKs.\",\n      \"evidence\": \"yeast two-hybrid, in vitro kinase assays, RAS pulldowns, EGF-stimulated HeLa cells\",\n      \"pmids\": [\"8621729\", \"7969158\", \"7565670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of differential coupling in vivo not established\", \"Mechanistic basis of selectivity incomplete\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the substrate-recognition determinants by showing the ERK phosphorylation lip dictates MEK1/MEK2 specificity, explaining the dual-specificity reaction at residue level.\",\n      \"evidence\": \"site-directed mutagenesis of ERK1 with in vitro phosphorylation\",\n      \"pmids\": [\"8626767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MEK2-side recognition residues not mapped\", \"Did not address non-ERK substrates\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated MEK2 is dispensable for development due to MEK1 compensation, framing the redundancy question central to MEK biology.\",\n      \"evidence\": \"germline Mek2-null mouse with phenotypic analysis\",\n      \"pmids\": [\"12832465\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test combined MEK dosage\", \"Non-redundant cell-type-specific roles not excluded\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Provided the structural basis for noncompetitive allosteric inhibition by capturing MEK2 locked in an inactive conformation, defining a druggable pocket.\",\n      \"evidence\": \"X-ray crystallography of MEK2 ternary complex with MgATP and inhibitor\",\n      \"pmids\": [\"15543157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active phosphorylated-state structure not determined\", \"Conformational dynamics of activation not captured\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Uncovered covalent regulation of MEK2 by pathogen-driven acetylation of activation-loop serines, revealing a competitive PTM that blocks activating phosphorylation.\",\n      \"evidence\": \"mass spectrometry mapping of YopJ acetylation sites and biochemical inhibition\",\n      \"pmids\": [\"17116858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous (non-pathogen) acetylation not addressed\", \"Reversibility by host deacetylases unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established the MEK1-MEK2 heterodimer and ERK feedback through MEK1-Thr292 as the mechanism by which MEK2 activity is negatively regulated.\",\n      \"evidence\": \"reciprocal Co-IP, phospho-specific blots, Thr292 mutagenesis, MEK1 knockout embryos\",\n      \"pmids\": [\"19219045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of heterodimer in vivo unclear\", \"Whether all MEK2 signaling passes through heterodimer unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed MEK2-activated ERK2 is biased to cytoplasmic, pro-survival output versus MEK1-driven nuclear proliferative output, assigning functional divergence to subcellular ERK fate.\",\n      \"evidence\": \"siRNA, NES constructs, fractionation/immunofluorescence, phosphosite mutagenesis\",\n      \"pmids\": [\"17928366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for cytoplasmic retention by MEK2 incomplete\", \"Generality across cell types not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Localized a MEK2 pool to endosomes via clathrin-dependent endocytosis acting in negative feedback, linking MEK2 trafficking to signal attenuation.\",\n      \"evidence\": \"GFP-MEK2 live imaging, clathrin/RAF siRNA, ERK readout in HeLa\",\n      \"pmids\": [\"18657070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endosomal substrates of MEK2 not identified\", \"Signal contribution of endosomal pool not quantified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a MEK dosage threshold for placental development and embryonic viability, showing combined MEK quantity rather than isoform identity is limiting.\",\n      \"evidence\": \"compound mutant allelic series with conditional Map2k1 deletion and histology\",\n      \"pmids\": [\"19304888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target requiring high MEK dose in placenta unknown\", \"Tissue-specific thresholds not fully mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Proved MEK1 and MEK2 are biochemically interchangeable by rescuing Mek1-null lethality with Mek2 coding sequence, settling that phenotypes reflect protein quantity not isoform-specific chemistry.\",\n      \"evidence\": \"knock-in rescue mouse genetics with embryo viability assays\",\n      \"pmids\": [\"26814233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cannot explain isoform-specific findings in cultured cells\", \"Regulatory (non-coding) differences not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Multiple ERK-independent and non-canonical MEK2 functions are reported but their integration with the canonical cascade and physiological weight remain unresolved.\",\n      \"evidence\": \"scattered single-lab studies on GCIP, p53R2/RNR, Pin1-BPGAP1, p38, PI3Kδ, EV uptake, and myelination\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Most non-canonical substrates rest on single Co-IP/activity studies without reciprocal validation\", \"Whether kinase activity versus scaffolding drives each function is inconsistent\", \"Reconciliation with strict MEK1/MEK2 redundancy in vivo is unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 3, 15, 28]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 15]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9, 12]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 8]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [10, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [25, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [21, 22, 27]}\n    ],\n    \"complexes\": [\n      \"MEK1-MEK2 heterodimer\",\n      \"RAS:RAF-1:MEK1 complex (MEK2 excluded)\"\n    ],\n    \"partners\": [\n      \"MAP2K1\",\n      \"RAF1\",\n      \"ARAF\",\n      \"MAP3K1\",\n      \"USP21\",\n      \"PIN1\",\n      \"RMRP\",\n      \"DLG1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}